6FV.F SOFTOX SOLUTIONS NK 002
- Market cap
- EUR 27.1M
- P/E
- -
- P/B
- 12.46x
- ROE
- -47.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 6FV.F undervalued?
Graham numberThe Graham number of SOFTOX SOLUTIONS NK 002 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
SOFTOX SOLUTIONS NK 002 fundamental analysis
No fundamental analysis for SOFTOX SOLUTIONS NK 002 yet.
SOFTOX SOLUTIONS NK 002 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About SOFTOX SOLUTIONS NK 002
SoftOx Solutions AS, together with its subsidiaries, operates as a clinical-stage pharmaceutical company that anti-infective therapy for airway infections in Norway. The company develops SIS-03, a lead clinical program that is in phase 2a to treatment of chronic airway infections. It also developing pan antimicrobial pharmaceuticals targeting bacteria, viruses, yeast, spores, and fungi. SoftOx Solutions AS was founded in 2012 and is based in Lysaker, Norway.
Full company profileSOFTOX SOLUTIONS NK 002 financial statements
SOFTOX SOLUTIONS NK 002 annual financial statements (NOK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -86.1M | -91.1M | -32.6M | -32.5M | -11.4M |
| EBITDA | - | -87.6M | -25.7M | -35.9M | -8.18M |
| Net Income | -65.4M | -71.1M | -39.4M | -42.9M | -10.8M |
| EPS | -1.63 | -1.77 | -0.95 | -0.02 | 0.00 |
| Balance Sheet | |||||
| Total Assets | 128M | 101M | 97.2M | 121M | 33.9M |
| Total Liabilities | 18.3M | 61.8M | 94.9M | 26.0M | 11.0M |
| Shareholders' Equity | 110M | 38.7M | 2.37M | 95.2M | 23.0M |
| Cash & Short-term Investments | 57.0M | 6.91M | 7.65M | 10.5M | 19.8M |
| Cash Flow | |||||
| Operating Cash Flow | -72.6M | -85.9M | 757K | 32.6M | -18.9M |
| Capital Expenditure | 4.60M | 4.85M | 7.61M | 19.8M | 0.00 |
| Free Cash Flow | -77.2M | -90.8M | -6.85M | 32.6M | -18.9M |
| Ratios | |||||
| ROE | -59.6% | -183.6% | -1,667.1% | -45.1% | -47.1% |
| ROA | -51.1% | -70.7% | -40.6% | -35.4% | -31.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
SOFTOX SOLUTIONS NK 002 dividends
SOFTOX SOLUTIONS NK 002 has not paid dividends in the last 5 fiscal years.
Who owns SOFTOX SOLUTIONS NK 002
- Insiders 38.20%
- Institutions 5.81%
- Public & others 55.99%
- Shares outstanding 2.71B
- Free float 1.68B
SOFTOX SOLUTIONS NK 002 company profile
- Company name
- SOFTOX SOLUTIONS NK 002
- Ticker
- 6FV.F
- ISIN
- NO0010811961
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2
- Fiscal year end
- December
- Address
- Fridtjof Nansens vei 16, Lysaker, Norway, 1364
- Phone
- 47 91 87 61 65
- Website
- soft-ox.com
About SOFTOX SOLUTIONS NK 002
SoftOx Solutions AS, together with its subsidiaries, operates as a clinical-stage pharmaceutical company that anti-infective therapy for airway infections in Norway. The company develops SIS-03, a lead clinical program that is in phase 2a to treatment of chronic airway infections. It also developing pan antimicrobial pharmaceuticals targeting bacteria, viruses, yeast, spores, and fungi. SoftOx Solutions AS was founded in 2012 and is based in Lysaker, Norway.
SOFTOX SOLUTIONS NK 002 management
5- Mr. Ulrik SporkExecutive Chairman of the Board
- Mr. Thomas BjarnsholtCEO, Chief Medical Officer & Chief Scientific Officer
- Ms. Ingrid JuvenCOO & CFO
- Ms. Charlotte PinholtHead of CMC
- Ms. Elin Lisby Kastberg JørgensenInternational Senior Project Manager